Moderna's stock price surged by up to 7% overnight, reaching a new high since January 2022, with its total market capitalization briefly approaching $96 billion. Year-to-date, its stock has cumulatively risen over 650%, primarily driven by market attention to the progress of its mRNA cancer vaccine, intismeran, in combination with Keytruda (pembrolizumab) in Phase III trials. Full detailed data from this trial will be presented at the European Society for Medical Oncology (ESMO) annual meeting in Madrid, Spain, from October 23 to 27. However, analysts are divided on the company's valuation, with a consensus target price of $122.67, and Citi even downgraded its rating to "Sell" with a target price of $80.